Product Pipeline


Xenon is focused on advancing our ion channel neurology pipeline.

The products within our novel proprietary pipeline – including clinical-stage candidates XEN496 and XEN1101 – are aimed at treating neurological disorders, with a particular focus on epilepsy. We intend to pursue a variety of development strategies, such as those focused on using a “precision medicine” approach to address rare pediatric disorders, including KCNQ2 epilepsy, as well as those targeting broader patient populations, such as adult patients with focal epilepsy. We also have promising partnered products within our pipeline, such as NBI-921352 with Neurocrine Biosciences and PCRX301 with Pacira BioSciences.



Preclinical
Phase 1
Phase 2
Phase 3
Approved

XEN1101

for Adult Focal Epilepsy
X-TOLE Clinical Trial

XEN1101

for Major Depressive Disorder (MDD)
Investigator-led Phase 2 POC study Collaboration with Mount Sinai

XEN1101

for MDD
Company-sponsored Phase 2 POC study

XEN496

for Orphan Pediatric Epilepsy (KCNQ2-DEE)
EPIK Clinical Trial

NBI-921352

for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences

NBI-921352

for Focal-Onset Seizures in Adults
Partnered with Neurocrine Biosciences

PCRX301

for Post-Operative Pain
Partnered with Pacira BioSciences


Medical Affairs

Learn more about our ongoing clinical trials

View Medical Affairs
Publications

See publications related to our clinical development candidates

View Publications
Partners

Find out more about collaborating with Xenon

View Partners